Aktiesnakken — Maj 2011
-
20 mill dollars for at file
-
hvilken responserate for dara skal vi se
-
hvis der overhovedet er respons i mono så er det godt, fordi ingen antistoffer har vist noget her
-
very significant interest fra pharma på dara
-
bare reponse er godt
-
--- aslut ----
-
overraskende godt (internationalt) fremmøde og spørgelyst...... er selskabet mon på vej tilbage i varmen?
-
ja måske...
-
Vi kører videre med D/S norden
-
-
spot tanker markedet er godt
-
east of suez less attractive
-
fleet growth er mindskende
-
de fastholder forventninger
-
aka fortsætter med DNORD webcast-referat i IR-live.... hvis nogle er interesserede.
-
ebit 55-95 uden skibssalg
-
så er der Q&A
-
de guider stadig konservativt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind